Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · June 25, 2021

Metastatic Renal Cell Carcinoma Patient With Indolent Disease

Written by
Nazli Dizman MD

 

Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Roberto Arata

    Jun 26, 2021

    Active survillance .TC in 3 months

  • Andre Tofoli

    Jul 02, 2021

    Roberto Arata, I completely agree. 

  • İsmail Beypınar

    Jul 03, 2021

    Although the nodules are so small for surgery, active surveillance may be the most appropriate option after stereotactic radiosurgery.

  • Roberto Arata

    Jul 04, 2021

    I completely agree about streotactic radiosurgery .

  • puthuveettil jayaprakash

    Jul 04, 2021

    Stereotactic radiosurgery is an option, if surveillance is continued

  • Mar 03, 2024

    Pending Moderator approval.
    Delete

Further Reading